The tumor necrosis factor α (TNF-α) antagonists infliximab, adalimumab, and certolizumab pegol are highly effective in the treatment of inflammatory bowel disease (IBD), with all 3 agents approved for Crohn disease and infliximab and adalimumab approved for ulcerative colitis.
1-6